Sarepta says its experimental Duchenne drug more effective than older medicine

(Corrects media packaging code; no changes to text)

(Reuters) -Sarepta Therapeutics said on Monday a mid-stage trial showed its experimental drug produced higher levels of a specific protein deficient in some patients with Duchenne muscular dystrophy (DMD), a muscle wasting disorder, than its older drug Exondys 51.

(Reporting by Leroy Leo in Bengaluru; Editing by Shailesh Kuber)